FET PET-based target volume delineation for the radiotherapy of glioblastoma: A pictorial guide to help overcome methodological pitfalls.

AG-NRO-06 ARO-2024–01 Biological tumor volume (BTV) FET PET Glioblastoma NCT05871021 PRIDE trial (NOA-28 Treatment planning

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
14 Jun 2024
Historique:
received: 15 04 2024
revised: 06 06 2024
accepted: 12 06 2024
medline: 17 6 2024
pubmed: 17 6 2024
entrez: 16 6 2024
Statut: aheadofprint

Résumé

PET is increasingly used for target volume definition in the radiotherapy of glioblastoma, as endorsed by the 2023 ESTRO-EANO guidelines. In view of its growing adoption into clinical practice and upcoming PET-based multi-center trials, this paper aims to assist in overcoming common pitfalls of FET PET-based target delineation in glioblastoma.

Identifiants

pubmed: 38880414
pii: S0167-8140(24)00656-X
doi: 10.1016/j.radonc.2024.110386
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110386

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Adrien Holzgreve (A)

Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany; Ahmanson Translational Theranostics Division, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, USA. Electronic address: Adrien.Holzgreve@med.lmu.de.

Alexander Nitschmann (A)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

Sebastian H Maier (SH)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; Bavarian Cancer Research Center (BZKF), Munich, Germany.

Marcel Büttner (M)

Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany.

Stephan Schönecker (S)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

Sebastian N Marschner (SN)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

Daniel F Fleischmann (DF)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

Stefanie Corradini (S)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; Bavarian Cancer Research Center (BZKF), Munich, Germany.

Claus Belka (C)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; Bavarian Cancer Research Center (BZKF), Munich, Germany; German Cancer Consortium (DKTK), Munich, Germany.

Christian la Fougère (C)

Department of Nuclear Medicine, University Hospital Tübingen, Tübingen, Germany.

Raphael Bodensohn (R)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany.

Nathalie L Albert (NL)

Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany; Bavarian Cancer Research Center (BZKF), Munich, Germany; German Cancer Consortium (DKTK), Munich, Germany.

Maximilian Niyazi (M)

Bavarian Cancer Research Center (BZKF), Munich, Germany; Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany; German Cancer Consortium (DKTK), Tübingen, Germany.

Classifications MeSH